FDA Approves ZYRTEC HIVES — Kenvue Brands LLC
Kenvue Brands LLC has announced that the FDA has approved the antihistamine Cetirizine Hydrochloride (ZYRTEC HIVES) via BLA NDA019835. This approval strengthens the company’s oral allergy portfolio, leveraging the established efficacy of this 1995-established brand.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day